“The practicality of relying on only generics to meet the pharmaceutical needs of a patient population is questionable. While these formularies and benefit designs gained some momentum starting in 2006 when Medicare Part D plan sponsors attempted to provide some coverage for patients in the ‘doughnut hole’ of their Part D benefit by covering generics only, it is generally not realistic to believe that a formulary of only generics will meet all of the contemporary clinical needs of a patient.”
— Allan Zimmerman, a director in the PricewaterhouseCoopers Human Resources Services Practice, told AIS’s Drug Benefit News.
No comments:
Post a Comment